Key result
Pegylated liposomal doxorubicin and paclitaxel yield ~48% response rate without cardiac toxicity in breast cancer.
Why the study?
The combination of paclitaxel and doxorubicin or epirubicin is highly active against metastatic breast cancer but may cause congestive heart failure, and liposome-encapsulated doxorubicin offers a formulation with no dose-limiting cardiac toxicity.
Does the combination of pegylated liposomal doxorubicin and paclitaxel improve response rates without causing cardiac toxicity in patients with previously treated metastatic breast cancer?
Does the combination of pegylated liposomal doxorubicin and paclitaxel improve response rates without causing cardiac toxicity in patients with previously treated metastatic breast cancer?
The combination of pegylated liposomal doxorubicin and weekly paclitaxel is highly effective for previously treated metastatic breast cancer and avoids the dose-limiting cardiac toxicity typically associated with conventional doxorubicin.
Answers are grounded in this paper and cite their sources.
Supports further investigation in pretreated metastatic breast cancer; leaves open comparative efficacy and durability in randomized trials.
The combination of paclitaxel and doxorubicin or epirubicin is highly active against metastatic breast cancer, yet may produce congestive heart failure. Liposome-encapsulated doxorubicin is a new formulation of doxorubicin with no dose-limiting cardiac toxicity. Twenty-one patients with metastatic breast cancer were treated with pegylated liposomal doxorubicin (20 mg/m2, day 1) and paclitaxel (100 mg/m2, days 1 and 8) for six cycles every 2 weeks. All patients had had relapse or progression on one to five previous chemotherapies. We observed two patients with complete and eight patients with partial remissions (48% response rate). Eight of the 10 responders had had previous therapy with epirubicin, doxorubicin or mitoxantrone. The mean remission duration was 5 months. Disease progression due to brain metastasis occurred in five cases. Severe side effects (grade 3 WHO) were alopecia (100%), skin toxicity in 29%, neuropathy in 24% and mucositis in 13%. Leukopenia (grade 4 WHO) was observed in 48%, but there was no cardiac toxicity, no death and no hospitalization. The combination of weekly paclitaxel and liposomal doxorubicin every 2 weeks is highly effective in previously treated patients. Based on the doses we administered, we recommend 15 mg/m2 liposomal doxorubicin every 2 weeks and 80 mg/m2 paclitaxel weekly.
No takes yet. Share an insight, caveat, or question.
Schwonzen et al. (2000) studied metastatic breast cancer (n=21). Pegylated liposomal doxorubicin and paclitaxel was evaluated on Response rate (complete and partial remissions). Pegylated liposomal doxorubicin combined with weekly paclitaxel achieved a 48% response rate in previously treated metastatic breast cancer patients, with no cardiac toxicity observed.
Synapse has enriched 10 related papers. Consider them for comparative context: